ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhibition of Anaphylaxis by Ibrutinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03149315
Recruitment Status : Completed
First Posted : May 11, 2017
Last Update Posted : November 16, 2018
Sponsor:
Collaborator:
Feinberg School of Medicine, Northwestern University
Information provided by (Responsible Party):
Anne Marie Singh, MD, Ann & Robert H Lurie Children's Hospital of Chicago

Brief Summary:
This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulineia (WM). We propose to administer this approved drug to adults with food allergy to inhibit food allergy responses.

Condition or disease Intervention/treatment Phase
Food Allergy Anaphylaxis Food Drug: Ibrutinib Phase 2

Detailed Description:
This is open-label study designed to determine the fewest doses and shortest length of time, from two days to up to 7 days, needed for ibrutinib to fully inhibit tests for food allergy, and to determine the length of persistence of efficacy after the drug is stopped.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Inhibition of Anaphylaxis by Ibrutinib
Actual Study Start Date : April 10, 2017
Actual Primary Completion Date : November 14, 2018
Actual Study Completion Date : November 14, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anaphylaxis
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: Open Label Administration
Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
Drug: Ibrutinib
Ibrutinib 420mg, PO once daily for 2-7 days
Other Name: Ibruvica




Primary Outcome Measures :
  1. Length of treatment for skin prick test [ Time Frame: 30 days ]
    To determine the fewest ibrutinib doses required to eliminate food skin prick reactivity


Secondary Outcome Measures :
  1. Length of treatment for basophil reactivity [ Time Frame: 30 days ]
    To determine the fewest ibrutinib doses required to eliminate basophil reactivity to food antigen

  2. Skin compared to basophil reactivity [ Time Frame: 30 days ]
    To determine the timing of when skin prick testing (SPT) response to peanut or tree nuts is altered compared to basophil activation test (BAT) responses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of food allergy to peanut (or tree nut).
  • Male or female age ≥ 18 years.
  • Positive skin prick testing and basophil activation test to the trigger food, either peanut or tree nut.
  • Adequate organ and marrow function as defined below:
  • leukocytes ≥ 3,000/mcL
  • absolute neutrophil count ≥ 1,500/mcL
  • platelets ≥ 100,000/mcl
  • total bilirubin within normal institutional limits
  • AST(SGOT)/ALT(SPGT) within normal institutional limits
  • Creatinine within normal institutional limits
  • Women of child bearing potential must agree to two forms of highly effective contraception (hormonal, device, or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the Principal Investigator and her treating physician immediately.
  • A female of child bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Ability to understand and the willingness to sign a written informed consent.
  • Ability to clearly understand and speak English at an 8th grade reading level. For safety reasons, subjects must speak English due to the anticipated need for clear and timely communication with investigators and the study team in emergency situations, since the investigators and study team are English speaking.

Exclusion Criteria:

  • Subjects who have been on immunomodulatory therapies or oral corticosteroids within 1 month prior to study participation will be excluded, and those taking antihistamines must stop these drugs for one week prior to enrollment and must refrain from taking antihistamines during the duration of the study so as not to interfere with SPT responses.
  • Subjects with symptoms not consistent with type 1 food reactions (atopic dermatitis, eosinophilic esophagitis and any other non-IgE-mediated food sensitivities) will be excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib.
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, beta-blocker use or psychiatric illness/social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  • Subjects on anticoagulants, anti-platelet therapy, or any other predisposition towards bleeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03149315


Locations
United States, Illinois
Ann & Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
Feinberg School of Medicine, Northwestern University
Investigators
Principal Investigator: Anne Marie Singh, MD Ann & Robert H. Lurie Childrens Hospital
Principal Investigator: Bruce Bochner, MD Northwestern Feinberg School of Medicine

Responsible Party: Anne Marie Singh, MD, Attending Physician, Associate Professor of Pediatrics and Medicine, Ann & Robert H Lurie Children's Hospital of Chicago
ClinicalTrials.gov Identifier: NCT03149315     History of Changes
Other Study ID Numbers: 2016-357
First Posted: May 11, 2017    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Food Hypersensitivity
Anaphylaxis
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases